Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In Europe, azacitidine is the only hypomethylating agent approved for the treatment of patients with int-2-/high-risk myelodysplastic syndromes, offering significantly improved survival compared with conventional care. However, not all patients treated with azacitidine respond to treatment, and the vast majority of responders subsequently relapse. Currently, no standard care regimens have been established for patients after failure of azacitidine. Here, we discuss treatment options after loss of response or progression on azacitidine. In addition, we briefly consider optimization of first-line treatment along with potential biomarkers for identifying and monitoring response during treatment with azacitidine.

Original publication

DOI

10.1016/j.leukres.2014.09.008

Type

Journal article

Journal

Leuk Res

Publication Date

12/2014

Volume

38

Pages

1381 - 1391

Keywords

Azacitidine, Consensus, Hypomethylating agents, MDS, Refractory, Relapse, Salvage therapy, Antimetabolites, Antineoplastic, Azacitidine, Biomarkers, Disease-Free Survival, Europe, Humans, Myelodysplastic Syndromes, Practice Guidelines as Topic, Risk Factors, Survival Rate